PL335378A1 - Derivatives of inverse hydroxamates as metaloprotease inhibitors - Google Patents
Derivatives of inverse hydroxamates as metaloprotease inhibitorsInfo
- Publication number
- PL335378A1 PL335378A1 PL98335378A PL33537898A PL335378A1 PL 335378 A1 PL335378 A1 PL 335378A1 PL 98335378 A PL98335378 A PL 98335378A PL 33537898 A PL33537898 A PL 33537898A PL 335378 A1 PL335378 A1 PL 335378A1
- Authority
- PL
- Poland
- Prior art keywords
- hydroxamates
- inverse
- derivatives
- metaloprotease
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/135—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Detergent Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3911297P | 1997-02-26 | 1997-02-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
PL335378A1 true PL335378A1 (en) | 2000-04-25 |
Family
ID=21903750
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL98335378A PL335378A1 (en) | 1997-02-26 | 1998-02-24 | Derivatives of inverse hydroxamates as metaloprotease inhibitors |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP1019386A1 (en) |
JP (1) | JP2001513767A (en) |
KR (1) | KR20000075681A (en) |
AP (1) | AP9901631A0 (en) |
AR (1) | AR013070A1 (en) |
AU (1) | AU6822398A (en) |
BR (1) | BR9807763A (en) |
CA (1) | CA2281664A1 (en) |
HR (1) | HRP980096A2 (en) |
IS (1) | IS5159A (en) |
NO (1) | NO994103L (en) |
PE (1) | PE59199A1 (en) |
PL (1) | PL335378A1 (en) |
TR (1) | TR199902063T2 (en) |
WO (1) | WO1998038179A1 (en) |
ZA (1) | ZA981532B (en) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6235786B1 (en) | 1997-08-06 | 2001-05-22 | Abbott Laboratories | Reverse hydroxamate inhibitors of matrix metalloproteinases |
US6294573B1 (en) | 1997-08-06 | 2001-09-25 | Abbott Laboratories | Reverse hydroxamate inhibitors of matrix metalloproteinases |
JP2002502815A (en) | 1998-02-07 | 2002-01-29 | ブリティッシュ バイオテック ファーマシューティカルズ リミテッド | Antibacterial agent |
GB9818621D0 (en) * | 1998-08-26 | 1998-10-21 | Glaxo Group Ltd | Formamide compounds as therapeutic agents |
WO2000012466A1 (en) * | 1998-08-26 | 2000-03-09 | Glaxo Group Limited | Formamide compounds as therapeutic agents |
AU5582899A (en) * | 1998-08-26 | 2000-03-21 | Glaxo Group Limited | Formamides as therapeutic agents |
US6288261B1 (en) | 1998-12-18 | 2001-09-11 | Abbott Laboratories | Inhibitors of matrix metalloproteinases |
US6329550B1 (en) | 1998-12-31 | 2001-12-11 | Aventis Pharmaceuticals Inc. | Amidomalonamides useful as inhibitors of MMP of matrix metalloproteinase |
GB9918869D0 (en) * | 1999-08-10 | 1999-10-13 | British Biotech Pharm | Antibacterial agents |
JP2003081838A (en) * | 2001-09-11 | 2003-03-19 | Rohto Pharmaceut Co Ltd | Glucosamine preparation |
EP1476168A2 (en) | 2002-02-04 | 2004-11-17 | ALFAMA-Investigacao e Desenvolvimento de Produtos Farmaceuticos Lda. | Use of co-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases |
WO2004071384A2 (en) * | 2003-02-11 | 2004-08-26 | Boehringer Ingelheim International Gmbh | New pharmaceutical compositions based on anticholinergics and tace-inhibitors |
US20070203244A1 (en) * | 2006-02-09 | 2007-08-30 | Strongin Alex Y | Inhibitors of membrane type-1 matrix metalloproteinase for the treatment of insulin-dependent diabetes mellitus |
EP2234608A2 (en) | 2007-12-11 | 2010-10-06 | Viamet Pharmaceuticals, Inc. | Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties |
EA022505B1 (en) | 2008-03-25 | 2016-01-29 | Эффектис Фармасьютиклз Аг | Novel p2x7r antagonists and their use |
DK2243772T3 (en) | 2009-04-14 | 2012-02-13 | Affectis Pharmaceuticals Ag | New P2X7R antagonists and their use |
WO2012110190A1 (en) | 2011-02-17 | 2012-08-23 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
US9163044B2 (en) | 2011-04-19 | 2015-10-20 | Alfama, Inc. | Carbon monoxide releasing molecules and uses thereof |
WO2012163456A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
WO2012163792A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
EP2734235B1 (en) | 2011-07-21 | 2017-03-22 | Alfama, Inc. | Ruthenium carbon monoxide releasing molecules and uses thereof |
WO2020070239A1 (en) | 2018-10-04 | 2020-04-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Egfr inhibitors for treating keratodermas |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9223904D0 (en) * | 1992-11-13 | 1993-01-06 | British Bio Technology | Inhibition of cytokine production |
US6037472A (en) * | 1993-11-04 | 2000-03-14 | Syntex (U.S.A.) Inc. | Matrix metalloprotease inhibitors |
WO1995019956A1 (en) * | 1994-01-20 | 1995-07-27 | British Biotech Pharmaceuticals Limited | Metalloproteinase inhibitors |
GB9514867D0 (en) * | 1995-07-20 | 1995-09-20 | British Biotech Pharm | Metalloproteinase inhibitors |
EP0873304B1 (en) * | 1995-11-23 | 2001-09-05 | British Biotech Pharmaceuticals Limited | Metalloproteinase inhibitors |
-
1998
- 1998-02-24 HR HR60/039,112A patent/HRP980096A2/en not_active Application Discontinuation
- 1998-02-24 JP JP53728498A patent/JP2001513767A/en active Pending
- 1998-02-24 TR TR1999/02063T patent/TR199902063T2/en unknown
- 1998-02-24 BR BR9807763-5A patent/BR9807763A/en not_active Application Discontinuation
- 1998-02-24 AP APAP/P/1999/001631A patent/AP9901631A0/en unknown
- 1998-02-24 WO PCT/EP1998/001015 patent/WO1998038179A1/en not_active Application Discontinuation
- 1998-02-24 PL PL98335378A patent/PL335378A1/en unknown
- 1998-02-24 AU AU68223/98A patent/AU6822398A/en not_active Abandoned
- 1998-02-24 ZA ZA9801532A patent/ZA981532B/en unknown
- 1998-02-24 CA CA002281664A patent/CA2281664A1/en not_active Abandoned
- 1998-02-24 KR KR1019997007747A patent/KR20000075681A/en not_active Application Discontinuation
- 1998-02-24 EP EP98913575A patent/EP1019386A1/en not_active Withdrawn
- 1998-02-25 AR ARP980100842A patent/AR013070A1/en unknown
- 1998-02-25 PE PE1998000138A patent/PE59199A1/en not_active Application Discontinuation
-
1999
- 1999-08-20 IS IS5159A patent/IS5159A/en unknown
- 1999-08-25 NO NO994103A patent/NO994103L/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP1019386A1 (en) | 2000-07-19 |
NO994103D0 (en) | 1999-08-25 |
HRP980096A2 (en) | 1998-12-31 |
ZA981532B (en) | 1999-08-24 |
AR013070A1 (en) | 2000-12-13 |
NO994103L (en) | 1999-10-25 |
AU6822398A (en) | 1998-09-18 |
CA2281664A1 (en) | 1998-09-03 |
TR199902063T2 (en) | 1999-12-21 |
BR9807763A (en) | 2000-02-22 |
WO1998038179A1 (en) | 1998-09-03 |
AP9901631A0 (en) | 1999-09-30 |
IS5159A (en) | 1999-08-20 |
JP2001513767A (en) | 2001-09-04 |
KR20000075681A (en) | 2000-12-26 |
PE59199A1 (en) | 1999-06-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL335378A1 (en) | Derivatives of inverse hydroxamates as metaloprotease inhibitors | |
PL333918A1 (en) | Derivatives of 6-phenylpyryidil-2-amine useful as nos inhibitors | |
PL334846A1 (en) | Sulphamidic inhibitors of metaloproteases | |
PL331856A1 (en) | Heterocyclic inhibitors of metaloprotease | |
PL327569A1 (en) | Promedications of thrombosin inhibitors | |
AU4429799A (en) | Inhibitors of p38 | |
AU1271297A (en) | Inhibitor of ceramidase | |
ZA98376B (en) | Sulfamide-metalloprotease inhibitors | |
HU9702036D0 (en) | New heterocyclic compounds as inhibitors of leucocita-adhesion and wla-4-antagonists | |
PL339551A1 (en) | Derivatives of rezorcin | |
IL127260A0 (en) | Hydroxy-phosphinyl derivatives useful as naaladase inhibitors | |
PL331047A1 (en) | Novel amidinic derivatives and their application as inhibitors of thrombosin | |
PL342113A1 (en) | Sulphonamidic derivatives useful as precursors of aspartil protease inhibitors | |
PL330915A1 (en) | Phenylaniline derivatives as inhibitors of integrin | |
PL337697A1 (en) | Farnesil-proteinous transferase inhibitors | |
PL331254A1 (en) | Phosphonianic inhibitors of matrix metaloproteases | |
PL331795A1 (en) | Heterocyclic metaloprotease inhibitors | |
PL337645A1 (en) | Novel amidine derivatives and their application as thrombosin inhibitors | |
HU0900792D0 (en) | Use of renin-angiotensin inhibitors | |
AU9317298A (en) | Pyrrolidin-2-one compounds and their use as neuraminidase inhibitors | |
PL334975A1 (en) | Application of gasto-intestinal lipase inhibitors | |
PL339176A1 (en) | Derivatives of pyrrolopyrrolone as inhibitors of neutrophilic elastase | |
GB9425701D0 (en) | Enzyme inhibitors | |
ZA983065B (en) | Inhibitors of protein farnesyltranferase | |
HU9503783D0 (en) | Squvalen syntetase inhibitors |